IL255198B - A purification platform for bispecific antibodies - Google Patents

A purification platform for bispecific antibodies

Info

Publication number
IL255198B
IL255198B IL255198A IL25519817A IL255198B IL 255198 B IL255198 B IL 255198B IL 255198 A IL255198 A IL 255198A IL 25519817 A IL25519817 A IL 25519817A IL 255198 B IL255198 B IL 255198B
Authority
IL
Israel
Prior art keywords
bispecific antibodies
purification platform
purification
platform
bispecific
Prior art date
Application number
IL255198A
Other languages
English (en)
Hebrew (he)
Other versions
IL255198A0 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL255198A0 publication Critical patent/IL255198A0/en
Publication of IL255198B publication Critical patent/IL255198B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3819—Affinity chromatography of the nucleic acid-nucleic acid binding protein type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL255198A 2014-07-26 2017-10-22 A purification platform for bispecific antibodies IL255198B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029463P 2014-07-26 2014-07-26
PCT/US2015/041936 WO2016018740A2 (en) 2014-07-26 2015-07-24 Purification platform for bispecific antibodies

Publications (2)

Publication Number Publication Date
IL255198A0 IL255198A0 (en) 2017-12-31
IL255198B true IL255198B (en) 2022-04-01

Family

ID=53836215

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255198A IL255198B (en) 2014-07-26 2017-10-22 A purification platform for bispecific antibodies

Country Status (19)

Country Link
US (1) US10626142B2 (https=)
EP (2) EP3912987B9 (https=)
JP (1) JP6702967B2 (https=)
KR (1) KR102440737B1 (https=)
CN (1) CN107074906B (https=)
AR (1) AR101262A1 (https=)
AU (1) AU2015298156B2 (https=)
DK (2) DK3172221T3 (https=)
EA (1) EA036154B1 (https=)
ES (2) ES2942533T3 (https=)
FI (1) FI3912987T3 (https=)
IL (1) IL255198B (https=)
MX (1) MX377558B (https=)
MY (1) MY187051A (https=)
PL (2) PL3172221T3 (https=)
SG (2) SG11201700157VA (https=)
TW (1) TWI704155B (https=)
WO (1) WO2016018740A2 (https=)
ZA (1) ZA201700622B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US10294306B2 (en) * 2015-05-28 2019-05-21 Bio-Rad Laboratories, Inc. Affinity ligands and methods relating thereto
CN108368166B (zh) * 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP6987424B2 (ja) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを洗浄および／または消毒する方法
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
CN109563124A (zh) * 2016-06-17 2019-04-02 豪夫迈·罗氏有限公司 多特异性抗体的纯化
WO2018038469A1 (ko) * 2016-08-20 2018-03-01 (주)아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
KR101933656B1 (ko) 2016-08-20 2018-12-28 (주) 아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
CN111902720B (zh) 2018-03-21 2025-02-07 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
GB201805142D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Bioprocess R&D Ab Separation method
MX2021001915A (es) 2018-08-17 2021-05-31 Regeneron Pharma Metodo y sistema de cromatografia para determinar la cantidad y pureza de una proteina multimerica.
CN112839959A (zh) * 2018-09-21 2021-05-25 特尼奥生物股份有限公司 用于纯化异源二聚多特异性抗体的方法
JPWO2020066270A1 (ja) * 2018-09-28 2021-08-30 株式会社カネカ κ鎖可変領域を含む抗体および／または抗体断片の製造方法
ES2962578T3 (es) 2018-10-31 2024-03-19 Regeneron Pharma Método y sistema de identificación y cuantificación de una proteína
BR112021005522A2 (pt) * 2018-11-21 2021-06-29 Regeneron Pharmaceuticals, Inc. anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, métodos de prevenção, tratamento ou melhoria de infecção por s. aureus, uma condição causada por infecção por s. aureus, ou pelo menos um sintoma de infecção por s. aureus, ou de diminuir a frequência ou gravidade de infecção por s. aureus, uma condição causada por infecção por s. aureus, de pelo menos um sintoma de infecção por s. aureus, para prevenir uma infecção por s. aureus, de prevenção, tratamento ou melhoria de infecção por s. aureus, ou de diminuir a frequência ou gravidade de infecção por s. aureus, em um indivíduo com um cateter, uma articulação protética ou qualquer outro objeto estranho, para prevenir, tratar ou melhorar a infecção estafilocócica, ou para diminuir a frequência ou gravidade da infecção estafilócica
CN112996801A (zh) * 2018-11-26 2021-06-18 北卡罗来纳州大学 用于捕获宿主细胞蛋白的肽配体
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
IL284317B2 (en) 2018-12-24 2025-10-01 Sanofi Sa Multispecific binding pseudo-fab proteins
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
SG11202112462RA (en) 2019-06-11 2021-12-30 Regeneron Pharma Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
MX2021015087A (es) * 2019-06-13 2022-01-18 Regeneron Pharma Metodos para eliminar componentes no deseados durante procesos cromatograficos de multiples etapas.
US11180540B2 (en) 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2021130717A1 (ko) * 2019-12-26 2021-07-01 에이비엘바이오 주식회사 단백질 a 친화성 크로마토그래피를 이용한 생리활성 펩티드의 정제 방법
KR102834449B1 (ko) 2019-12-27 2025-07-15 케이에스광학주식회사 투명한 방탄 적층 구조물
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
EP4281467A4 (en) * 2021-01-25 2024-12-04 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法
WO2023247468A2 (en) * 2022-06-22 2023-12-28 Puridify Limited Kappa light chain-binding convection matrix
US20250076310A1 (en) 2022-12-08 2025-03-06 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法
WO2025073922A1 (en) * 2023-10-04 2025-04-10 Sartorius Bia Separations D.O.O. Enhanced chromatographic separations of components in a mixture by employing chaotropic elution
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化
WO2025131519A1 (en) * 2023-12-21 2025-06-26 Cytiva Bioprocess R&D Ab Antibody separation with a vh3 binding separation matrix
WO2025173342A1 (ja) * 2024-02-13 2025-08-21 Jsr株式会社 Ｆｃ融合タンパク質を精製するためのクロマトグラフィー用担体、及びそれを用いたＦｃ融合タンパク質の精製方法
WO2026075981A1 (en) * 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Methods of analyzing heterodimeric proteins

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2169299T3 (es) 1996-09-03 2002-07-01 Gsf Forschungszentrum Umwelt Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.
ATE218143T1 (de) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
EP1115427B1 (de) 1998-09-25 2003-12-03 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20030224000A1 (en) 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
TWI372763B (en) * 2005-06-17 2012-09-21 Wyeth Llc Methods of purifying anti a beta antibodies
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CL2008000883A1 (es) 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
SG149759A1 (en) * 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
US20110166332A1 (en) * 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
KR101856792B1 (ko) * 2009-12-25 2018-05-11 추가이 세이야쿠 가부시키가이샤 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
RS67768B1 (sr) * 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
EP2500073A1 (en) * 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
PT2825559T (pt) * 2012-03-13 2019-06-07 Novimmune Sa Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
CA2886036A1 (en) * 2012-09-25 2014-04-03 Ichnos Sciences SA Purification of hetero-dimeric immunoglobulins
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos

Also Published As

Publication number Publication date
TW201617359A (zh) 2016-05-16
KR102440737B1 (ko) 2022-09-06
TWI704155B (zh) 2020-09-11
EA201790247A1 (ru) 2017-08-31
EP3912987B9 (en) 2023-05-31
JP2017524740A (ja) 2017-08-31
DK3912987T3 (da) 2023-05-01
EP3172221A2 (en) 2017-05-31
IL255198A0 (en) 2017-12-31
CN107074906B (zh) 2021-05-14
DK3172221T3 (da) 2021-08-09
US10626142B2 (en) 2020-04-21
KR20170035941A (ko) 2017-03-31
EP3172221B1 (en) 2021-07-07
MY187051A (en) 2021-08-27
EA036154B1 (ru) 2020-10-06
WO2016018740A2 (en) 2016-02-04
CN107074906A (zh) 2017-08-18
SG11201700157VA (en) 2017-02-27
PL3172221T3 (pl) 2021-12-27
EP3912987A1 (en) 2021-11-24
WO2016018740A8 (en) 2021-06-10
US20160024147A1 (en) 2016-01-28
ZA201700622B (en) 2020-05-27
ES2942533T3 (es) 2023-06-02
PL3912987T3 (pl) 2023-07-24
FI3912987T3 (fi) 2023-06-19
WO2016018740A3 (en) 2016-03-17
AR101262A1 (es) 2016-12-07
BR112017001443A2 (pt) 2017-12-05
MX2017001217A (es) 2017-05-03
AU2015298156A1 (en) 2017-02-23
MX377558B (es) 2025-03-10
JP6702967B2 (ja) 2020-06-03
NZ728700A (en) 2023-09-29
ES2881026T3 (es) 2021-11-26
CA2955618A1 (en) 2016-02-04
AU2015298156B2 (en) 2020-07-16
SG10201900661YA (en) 2019-02-27
EP3912987B1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
IL255198B (en) A purification platform for bispecific antibodies
IL282403B1 (en) Antibodies against pd-1
IL247478A0 (en) Bispecific antibodies against her2
IL250583A0 (en) Anti-tigit antibodies
PL3130606T3 (pl) Przeciwciała dwuswoiste aktywujące układ odpornościowy
PT3268390T (pt) Métodos de purificação de anticorpos biespecíficos
SG11201703344WA (en) Anti-pd-1 antibodies
IL252422A0 (en) Effector-deficient anti-cd32a antibodies
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
IL248697A0 (en) Methods for purifying antibodies
IL250374A0 (en) Antibodies against ceramide
EP3143154A4 (en) Chemically-locked bispecific antibodies
SG11201607098SA (en) Antibody purification process
ZA201704704B (en) Antibodies for il-17c
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
SG11201704540YA (en) Method for purifying easily polymerizable substance
IL272676B (en) Bispecific antibodies against il-4 and il-13
HK1234069A1 (en) Purification platform for bispecific antibodies
GB201419087D0 (en) Anti-PD-1 antibodies
GB201419080D0 (en) Anti-PD-1 antibodies
HK1235274A1 (en) Anti-il-4-il-13 bispecific antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies